TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06232525

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transobturator tape operation (TOT)
Description: TOT surgery: With an 18 French Foley urinary catheter, the sling passes through the skin in the groin, the obturator foramen, the back of the adductor longus tendon, and the midurethral vaginal incision; extends 1 cm below the midpoint of the urethra, the tape is held in place without sutures by its interface with the patient's tissue. After the mesh is placed, the incision in the suburethral midline is closed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: urethral ligament plication
Description: Urethral ligament plication: With an 18 French Foley urinary catheter, a vertical incision of approximately 3 cm is made in the anterior-lateral wall sulcus of the vagina on the right and left lines, 2 cm laterally from the midline, with the urethral meatus remaining in the midline, and external urethral ligaments on both sides inferolateral to the urethra, sutured in the midline by using 2-0 or 3-0 polyester sutures on both sides separately. The incised anterior vaginal tissue is closed one by one with 2-0 rapid Vicryl.
Study: NCT06686121

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Home Based Exercise
Description: This is a six month intervention where participants will walk at home for exercise with guidance from a study coach. They will attend two to four weekly meetings with the coach at the clinical site in the first 4 weeks following randomization, followed by once weekly telephone coaching calls for the remainder of the six-month intervention
Study: NCT06515041

Intervention type: OTHER
Group type: OTHER
Intervention: brain well-being
Description: Each volunteers will be subjected to an evaluation of his well-being using a previously well established well-being scale, through a list of questions, prior, during and after the visit to the museum. All volunteers will be also equipped with a non invasive NIRS system to measure their emotions (measure of tissus oxygenenation), with a non invasive system of eye tracking glasses to measure where their eyes are looking and with a non invasive system to measure their heart rate.

Intervention type: OTHER
Group type: OTHER
Intervention: brain well-being
Description: Each volunteers will be subjected to an evaluation of his well-being using a previously well established well-being scale, through a list of questions, prior, during and after the visit to the museum. All volunteers will be also equipped with a non invasive NIRS system to measure their emotions (measure of tissus oxygenenation), with a non invasive system of eye tracking glasses to measure where their eyes are looking and with a non invasive system to measure their heart rate.

Intervention type: OTHER
Group type: OTHER
Intervention: brain well-being
Description: Each volunteers will be subjected to an evaluation of his well-being using a previously well established well-being scale, through a list of questions, prior, during and after the visit to the museum. All volunteers will be also equipped with a non invasive NIRS system to measure their emotions (measure of tissus oxygenenation), with a non invasive system of eye tracking glasses to measure where their eyes are looking and with a non invasive system to measure their heart rate.
Study: NCT04784104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl 0.5% Injectable Solution
Description: 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl 0.5% Injectable Solution
Description: 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
Study: NCT06686121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrate Rich Beetroot Juice
Description: Participants will drink one shot of nitrate rich beet-root juice twice daily for six months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrate Rich Beetroot Juice
Description: Participants will drink one shot of nitrate rich beet-root juice twice daily for six months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control
Description: Participants will be asked to participate in weekly meetings with the coach in the attention control group for weeks 1-26. A staff member will present a topic from the National Institute on Aging age pages relevant to health, such as cancer screening or blood pressure treatment. Calls will last approximately 5-15 minutes and will focus on educational topics such as diabetes, healthy eating, and Medicare Part D.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: Participants will be asked to participate in weekly meetings with the coach in the attention control group for weeks 1-26. A staff member will present a topic from the National Institute on Aging age pages relevant to health, such as cancer screening or blood pressure treatment. Calls will last approximately 5-15 minutes and will focus on educational topics such as diabetes, healthy eating, and Medicare Part D.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beetroot Juice Without Nitrate
Description: Participants will drink one shot of placebo beetroot without nitrate juice twice daily for six months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beetroot Juice Without Nitrate
Description: Participants will drink one shot of placebo beetroot without nitrate juice twice daily for six months.
Study: NCT06687070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG -2449
Description: Orally once a day(QD), every 28 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG -2449
Description: Orally once a day(QD), every 28 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD
Description: Injected on the first day of each cycle, every 28 days as a cycle.
Study: NCT06688370

Intervention type: DEVICE
Intervention: Petit Drill
Description: Day 1: 2-4 doses, including one of the daily doses taken at bedtime. Days 2 and 3: 3 to 4 doses on days 2 and 3, including one of the daily doses taken at bedtime.
Study: NCT06687759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]MK-1084
Description: Oral administration
Study: NCT04976023

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 14.5 5 g twice daily for 8 weeks
Study: NCT06369610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given abiraterone acetate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing Hormone Analog
Description: Given SC or IM
Study: NCT06688604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: skin contact
Description: Ensuring mother-infant skin-to-skin contact by the researcher within the first 5 minutes after birth

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: skin contact
Description: Ensuring mother-infant skin-to-skin contact by the researcher within the first 5 minutes after birth
Study: NCT06688045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral administration
Study: NCT01442571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Study: NCT05918146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Dextrose injection plus physical therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline injection plus physical therapy
Study: NCT05406531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online
Description: This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology - online
Description: This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autogenic Training - online
Description: This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
Study: NCT06068361

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG
Description: 32-electrode EEG (resting state, passive auditory and active visual task)

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG
Description: 32-electrode EEG (resting state, passive auditory and active visual task)

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG
Description: 32-electrode EEG (resting state, passive auditory and active visual task)
Study: NCT05690204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAP-001
Description: Test the efficacy and safety of SAP-001 versus placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAP-001
Description: Test the efficacy and safety of SAP-001 versus placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAP-001
Description: Test the efficacy and safety of SAP-001 versus placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAP-001
Description: Test the efficacy and safety of SAP-001 versus placebo
Study: NCT05044039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Patients should take duvelisib at approximately the same time every day, with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Patients should take duvelisib at approximately the same time every day, with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Patients should take duvelisib at approximately the same time every day, with or without food.
Study: NCT06369610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing Hormone Analog
Description: Given SC or IM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT04883333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 153339
Description: LEO 153339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 153339
Description: LEO 153339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 153339
Description: LEO 153339
Study: NCT04784104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilocaine HCl 2% Injectable solution
Description: 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilocaine HCl 2% Injectable solution
Description: 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline amp. 0.5 mg
Description: 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
Study: NCT04883333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 153339
Description: LEO 153339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 153339
Description: LEO 153339
Study: NCT04784104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline amp. 0.5 mg
Description: 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
Study: NCT04883333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 153339
Description: LEO 153339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 153339
Description: LEO 153339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 153339
Description: LEO 153339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 153339
Description: LEO 153339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 153339
Description: LEO 153339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 153339
Description: LEO 153339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 153339
Description: LEO 153339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 153339
Description: LEO 153339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 153339
Description: LEO 153339

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05077501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACD856
Description: Multiple daily oral doses of ACD856 will be administered for 7 days in an escalation scheme of dose 1, dose 2 and dose 3. The escalation schedule may be adapted based on evaluation by the internal Safety Review Committee.
Study: NCT05894746

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: gluten-free
Description: see info in arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gluten-free
Description: see info in arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: gluten-free
Description: see info in arm description
Study: NCT04784104

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided supraclavicular block with coronal oblique method
Description: The blocks will be performed by an experienced anesthesiologist with a USG guidence.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided lateral sagittal infraclavicular block
Description: The blocks will be performed by an experienced anesthesiologist with USG guidence.
Study: NCT04924179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus Fruquintinib and SBRT
Description: Fruquintinib:5mg ,qd,po, d1-d14, 21 days for a cycle;Tislelizumab Injection:200mg，IV,d1,21 days for a cycle;SBRT:8-10Gy×5F,qod,in 10 days.
Study: NCT05894746

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic
Description: see info in arm description
Study: NCT04873128

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Multi-OMICS
Description: Measurement of gene expression in immune cells (Human Peripheral Blood Mononuclear Cell (PBMCs) or total blood) using functional genomics, proteomics, metabolomics and lipidomics tools and compare the dynamics of immune response before and after vaccination against COVID-19.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Multi-OMICS
Description: Measurement of gene expression in immune cells (Human Peripheral Blood Mononuclear Cell (PBMCs) or total blood) using functional genomics, proteomics, metabolomics and lipidomics tools and compare the dynamics of immune response before and after vaccination against COVID-19.
Study: NCT04731714

Intervention type: DEVICE
Group type: OTHER
Intervention: Rhythmic median nerve stimulation
Description: Square-wave 200 µs pulses triggered by computer at 12 Hz, at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.

Intervention type: DEVICE
Group type: OTHER
Intervention: Rhythmic median nerve stimulation
Description: Square-wave 200 µs pulses triggered by computer at 12 Hz, at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.

Intervention type: DEVICE
Group type: OTHER
Intervention: Arrhythmic median nerve stimulation
Description: Square-wave 200 µs pulses triggered by computer at random intervals with a mean rate of 12 Hz (as described in Morera Maiquez et al., 2020), at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.

Intervention type: DEVICE
Group type: OTHER
Intervention: Arrhythmic median nerve stimulation
Description: Square-wave 200 µs pulses triggered by computer at random intervals with a mean rate of 12 Hz (as described in Morera Maiquez et al., 2020), at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
Study: NCT06040645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APP Co-management
Description: To reduce additional burden of care on the PCPs, the investigators will incorporate Advanced Practices Providers into the patient education and self-management portion of care. The APPs will be trained together with the intervention physicians, but they will also undergo additional standardized training on patient education, UI knowledge, providing instruction on Kegel exercises, shared decision making, and self management.~Patients will then be scheduled for a UI education and self-management session with the APP by telemedicine (video visit or telephone visit) within one month of their initial visit. For patients in need of an annual pelvic examination, and if the patient's PCP prefers to have the APP conduct the pelvic exam, a separate visit will be scheduled with the APP. A followup televisit will then be scheduled within three months of the initial APP visit, in order to assess the outcome of non-surgical treatment and determine if a specialist referral is indicated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-consult
Description: In implementing the electronic consultation system in the private sector, the investigators will model the Expected Practice developed by the Los Angeles County Specialty-Primary Care Work Group. This eConsult system utilizes a kickback mechanism by which a specialist, who reviews the referral, can return it if it has not met certain baseline criteria (e.g. for a woman with OAB/urinary urgency: document negative UA, scheduled voids, titrate fluids to thirst, Kegels, antimuscarinics, optimize diuretic control, adjust any diuretics).
Study: NCT05866445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable BP device
Description: Wearable study BP device to be worn for 8 hours within study participation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable BP device
Description: Wearable study BP device to be worn for 8 hours within study participation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure monitor
Description: 24-hour ambulatory blood pressure monitor to be worn for 24-hours during study participation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure monitor
Description: 24-hour ambulatory blood pressure monitor to be worn for 24-hours during study participation.
Study: NCT04873713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Tape® aplicación
Description: Magnetic tape® is applied without creating any tension over low back

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiology Tape
Description: Kinesiology Tape is applied without creating any tension over low back